ICER Considers Fair Access Principles as Aduhelm Price Continues to Incense Critics

The Institute for Clinical and Economic Review (ICER) recently published its protocol detailing how it will gauge access to prescription drugs, in addition to its value assessments. Its recent revised report of Biogen’s Aduhelm found limited clinical benefit, leading experts to wonder if the drug’s $56,000 price tag is reasonable.

Healthcare Analyst Joshua Cohen remarks, “Whether or not ICER’s fair access to fairly priced drugs gets implemented for a therapeutic such as Aduhelm, this constitutes an important initiative with broad implications for the pharmaceutical market as a whole. Fair pricing of pharmaceuticals — in which price and value are aligned — and fair access — in which patients can actually obtain high-value care with minimal restrictions and co-payments — are two key objectives in pricing and reimbursement. ICER can play a constructive role in this regard.” Read more here.

(Source: Joshua Cohen, Forbes, 7/2/21)